It’s safe to assume that most people don’t associate Botox with overactive bladders, but doctors who use it to treat just a sliver of the 33 million people in the U.S. struggling with uncontrollable ...

A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301). Background: Response rates (55-65%) with ...